joris
Overview

IMMP

Cleared (data check passed)

Immutep Limited

9 programs · 1 analysed

Company data checked 2026-10-17 Framework v6.2.0

Pipeline

Every program the data service lists for this company, including ones that were stopped

Program BPIQ id Stage & event Catalyst (the big event, as given by the company) Analysed Materiality (how much it matters to the company)
Eftilagimod Alpha + Pembrolizumab Soft tissue sarcoma 17452 Phase 2 Data readout October 19, 2026 exact day given Yes Meaningful at the programme level, immaterial at the event level. Since 2026-09-11 neoadjuvant soft tissue sarcoma is one of the two indications the company intends to take into registration-directed trials, and it holds efti's only Orphan Drug Designation. But this catalyst is a health-related quality-of-life ePoster on a trial whose primary endpoint read out in May 2025, and it carries almost no new information about whether the drug works.
IMP761 (LAG-3 agonist) Autoimmune disease 18203 Phase 1 Data readout H2 2026 rough period (placeholder), not an exact day No Unfilled - not analysed. Phase 1 single ascending dose met its primary endpoint; multiple ascending dose phase under way; further updates guided to H2 2026. The 2026-08-19 version judged this row dominant; 03a C.2 does not allow a judgement on an unanalysed row, so that judgement is withdrawn rather than carried.
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) Metastatic breast cancer 13585 Phase 2/3 Update no big event No Unfilled - not analysed. AIPAC-003 closed 2026-06-30; CT.gov lists NCT05747794 as TERMINATED at 72 patients. Not named in the 2026-09-11 development focus.
Eftilagimod alfa (efti) + Keytruda Non-small cell lung carcinoma (1L NSCLC) 13791 Failed Discontinued Discontinued no big event No Unfilled - not analysed. FAILED / discontinued: TACTI-004, stopped for futility 2026-03-13. BPIQ has now set has_catalyst false on this row, which was true on 2026-08-19.
IMP761 (Agonist AB) COVID-19 14910 Failed Discontinued Discontinued no big event No Unfilled - not analysed. FAILED / discontinued pandemic-era indication.
Eftilagimod Alpha + KEYTRUDA and chemotherapy Non-small cell lung carcinoma (1L NSCLC) 16013 Phase 1 Update no big event No Unfilled - not analysed. INSIGHT-003 mature median OS 30.9 months (2026-07-13), single-arm, investigator-initiated.
Eftilagimod Alpha (LAG-3lg or IMP321) + Keytruda Head and neck squamous cell carcinoma (1L HNSCC) 18031 Failed Discontinued Discontinued no big event No Unfilled - not analysed. BPIQ marks this row FAILED / discontinued, but the company's release of 2026-09-11 names PD-L1-negative (CPS < 1) head and neck cancer as one of its two registration-directed focuses, with Fast Track designation. The feed and the company disagree; recorded in data_quality_flags, not resolved.
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and avelumab Solid tumor/s, Cancer, Urothelial cancer 18032 Failed Discontinued Discontinued no big event No Unfilled - not analysed. FAILED / discontinued. Kept as track record.
Neoadjuvant Eftilagimod Alfa (Efti) +/- SoC Early-stage HR+/HER2-negative breast cancer 19277 Phase 2 Update no big event No Unfilled - not analysed. On hold pending the TACTI-004 root cause analysis (BPIQ note 2026-07-30); CT.gov NCT07102940 NOT_YET_RECRUITING.

Attribution and cadence

Whether a share-price move can be tied to each program alone, or could come from another program's news, and whether the program is due for a refresh

Eftilagimod alfa (efti, IMP321) with pembrolizumab and radiotherapy
Contaminated Another program's result is due close to this one, so a price move cannot be tied to this event alone.
  • IMP761 (LAG-3 agonist) 2026-12-31 · BPIQ id 18203 · not yet analysed (BPIQ data row): overlaps, a date the company has given

Readout window opens 2026-10-19. Re-checks done: T-5, T-1 (T-5, T-2 and T-1 mean 5, 2 and 1 months before the window opens).

Locked stock calls

Each call shows the dates it covers, so calls made at the same time can be told apart by event

  1. 2026-10-19 → 2026-11-03 · Opens when the full abstract publishes on the ESMO Congress 2026 website (2026-10-19 00:05 CEST, before the first US and ASX sessions that day) and closes one week after the congress ends (2026-10-27), covering the abstract, ePoster 3788eP and any accompanying release. Anchored on readout.window, not catalyst_date (rule 23).

    EFTISARC-NEO health-related quality-of-life data, ESMO Congress 2026 abstract publication and ePoster

Price history

Daily closing prices and trading volume, with the dates of our re-checks marked

Eftilagimod alfa (efti, IMP321) with pembrolizumab and radiotherapy expected result window: 2026-10-19 to 2026-10-19, most likely 2026-10-19 52-week high $70.60 52-week low $3.06 IMMP close $3.20 on 2026-10-16 $70.60 $3.20 $3.06 Shares traded in the week: 28,335 · week ending 2021-08-20 Shares traded in the week: 76,075 · week ending 2021-08-27 Shares traded in the week: 124,260 · week ending 2021-09-03 Shares traded in the week: 48,985 · week ending 2021-09-10 Shares traded in the week: 68,265 · week ending 2021-09-17 Shares traded in the week: 47,720 · week ending 2021-09-24 Shares traded in the week: 70,195 · week ending 2021-10-01 Shares traded in the week: 33,240 · week ending 2021-10-08 Shares traded in the week: 54,495 · week ending 2021-10-15 Shares traded in the week: 84,175 · week ending 2021-10-22 Shares traded in the week: 78,805 · week ending 2021-10-29 Shares traded in the week: 59,585 · week ending 2021-11-05 Shares traded in the week: 383,930 · week ending 2021-11-12 Shares traded in the week: 72,340 · week ending 2021-11-19 Shares traded in the week: 45,165 · week ending 2021-11-26 Shares traded in the week: 68,165 · week ending 2021-12-03 Shares traded in the week: 68,795 · week ending 2021-12-10 Shares traded in the week: 69,870 · week ending 2021-12-17 Shares traded in the week: 32,400 · week ending 2021-12-23 Shares traded in the week: 35,255 · week ending 2021-12-31 Shares traded in the week: 37,685 · week ending 2022-01-07 Shares traded in the week: 27,070 · week ending 2022-01-14 Shares traded in the week: 30,705 · week ending 2022-01-21 Shares traded in the week: 126,765 · week ending 2022-01-28 Shares traded in the week: 31,430 · week ending 2022-02-04 Shares traded in the week: 23,290 · week ending 2022-02-11 Shares traded in the week: 20,900 · week ending 2022-02-18 Shares traded in the week: 40,625 · week ending 2022-02-25 Shares traded in the week: 43,240 · week ending 2022-03-04 Shares traded in the week: 68,750 · week ending 2022-03-11 Shares traded in the week: 38,560 · week ending 2022-03-18 Shares traded in the week: 59,095 · week ending 2022-03-25 Shares traded in the week: 27,965 · week ending 2022-04-01 Shares traded in the week: 12,610 · week ending 2022-04-08 Shares traded in the week: 23,155 · week ending 2022-04-14 Shares traded in the week: 21,055 · week ending 2022-04-22 Shares traded in the week: 24,755 · week ending 2022-04-29 Shares traded in the week: 22,140 · week ending 2022-05-06 Shares traded in the week: 23,845 · week ending 2022-05-13 Shares traded in the week: 18,175 · week ending 2022-05-20 Shares traded in the week: 38,640 · week ending 2022-05-27 Shares traded in the week: 63,915 · week ending 2022-06-03 Shares traded in the week: 40,850 · week ending 2022-06-10 Shares traded in the week: 42,170 · week ending 2022-06-17 Shares traded in the week: 21,655 · week ending 2022-06-24 Shares traded in the week: 16,875 · week ending 2022-07-01 Shares traded in the week: 15,250 · week ending 2022-07-08 Shares traded in the week: 17,320 · week ending 2022-07-15 Shares traded in the week: 11,505 · week ending 2022-07-22 Shares traded in the week: 10,625 · week ending 2022-07-29 Shares traded in the week: 10,010 · week ending 2022-08-05 Shares traded in the week: 14,580 · week ending 2022-08-12 Shares traded in the week: 19,505 · week ending 2022-08-19 Shares traded in the week: 10,930 · week ending 2022-08-26 Shares traded in the week: 17,205 · week ending 2022-09-02 Shares traded in the week: 7,315 · week ending 2022-09-09 Shares traded in the week: 17,170 · week ending 2022-09-16 Shares traded in the week: 10,650 · week ending 2022-09-23 Shares traded in the week: 11,075 · week ending 2022-09-30 Shares traded in the week: 29,605 · week ending 2022-10-07 Shares traded in the week: 17,145 · week ending 2022-10-14 Shares traded in the week: 8,920 · week ending 2022-10-21 Shares traded in the week: 9,300 · week ending 2022-10-28 Shares traded in the week: 25,070 · week ending 2022-11-04 Shares traded in the week: 42,605 · week ending 2022-11-11 Shares traded in the week: 19,260 · week ending 2022-11-18 Shares traded in the week: 29,490 · week ending 2022-11-25 Shares traded in the week: 44,965 · week ending 2022-12-02 Shares traded in the week: 22,710 · week ending 2022-12-09 Shares traded in the week: 78,165 · week ending 2022-12-16 Shares traded in the week: 173,225 · week ending 2022-12-23 Shares traded in the week: 49,820 · week ending 2022-12-30 Shares traded in the week: 18,820 · week ending 2023-01-06 Shares traded in the week: 26,410 · week ending 2023-01-13 Shares traded in the week: 11,145 · week ending 2023-01-20 Shares traded in the week: 26,940 · week ending 2023-01-27 Shares traded in the week: 14,720 · week ending 2023-02-03 Shares traded in the week: 8,720 · week ending 2023-02-10 Shares traded in the week: 10,475 · week ending 2023-02-17 Shares traded in the week: 10,850 · week ending 2023-02-24 Shares traded in the week: 13,445 · week ending 2023-03-03 Shares traded in the week: 10,025 · week ending 2023-03-10 Shares traded in the week: 15,500 · week ending 2023-03-17 Shares traded in the week: 63,375 · week ending 2023-03-24 Shares traded in the week: 17,465 · week ending 2023-03-31 Shares traded in the week: 18,515 · week ending 2023-04-06 Shares traded in the week: 15,995 · week ending 2023-04-14 Shares traded in the week: 49,955 · week ending 2023-04-21 Shares traded in the week: 25,895 · week ending 2023-04-28 Shares traded in the week: 16,490 · week ending 2023-05-05 Shares traded in the week: 15,915 · week ending 2023-05-12 Shares traded in the week: 4,331,620 · week ending 2023-05-19 Shares traded in the week: 330,070 · week ending 2023-05-26 Shares traded in the week: 112,500 · week ending 2023-06-02 Shares traded in the week: 74,700 · week ending 2023-06-09 Shares traded in the week: 63,175 · week ending 2023-06-16 Shares traded in the week: 39,235 · week ending 2023-06-23 Shares traded in the week: 54,945 · week ending 2023-06-30 Shares traded in the week: 58,950 · week ending 2023-07-07 Shares traded in the week: 36,405 · week ending 2023-07-14 Shares traded in the week: 67,815 · week ending 2023-07-21 Shares traded in the week: 46,865 · week ending 2023-07-28 Shares traded in the week: 56,200 · week ending 2023-08-04 Shares traded in the week: 27,425 · week ending 2023-08-11 Shares traded in the week: 24,150 · week ending 2023-08-18 Shares traded in the week: 27,730 · week ending 2023-08-25 Shares traded in the week: 34,810 · week ending 2023-09-01 Shares traded in the week: 21,440 · week ending 2023-09-08 Shares traded in the week: 31,735 · week ending 2023-09-15 Shares traded in the week: 19,545 · week ending 2023-09-22 Shares traded in the week: 25,765 · week ending 2023-09-29 Shares traded in the week: 13,595 · week ending 2023-10-06 Shares traded in the week: 22,040 · week ending 2023-10-13 Shares traded in the week: 73,695 · week ending 2023-10-20 Shares traded in the week: 108,905 · week ending 2023-10-27 Shares traded in the week: 36,920 · week ending 2023-11-03 Shares traded in the week: 25,275 · week ending 2023-11-10 Shares traded in the week: 25,665 · week ending 2023-11-17 Shares traded in the week: 28,440 · week ending 2023-11-24 Shares traded in the week: 22,015 · week ending 2023-12-01 Shares traded in the week: 27,760 · week ending 2023-12-08 Shares traded in the week: 108,525 · week ending 2023-12-15 Shares traded in the week: 44,980 · week ending 2023-12-22 Shares traded in the week: 20,760 · week ending 2023-12-29 Shares traded in the week: 19,310 · week ending 2024-01-05 Shares traded in the week: 47,210 · week ending 2024-01-12 Shares traded in the week: 30,280 · week ending 2024-01-19 Shares traded in the week: 22,865 · week ending 2024-01-26 Shares traded in the week: 23,520 · week ending 2024-02-02 Shares traded in the week: 18,015 · week ending 2024-02-09 Shares traded in the week: 16,415 · week ending 2024-02-16 Shares traded in the week: 22,660 · week ending 2024-02-23 Shares traded in the week: 20,655 · week ending 2024-03-01 Shares traded in the week: 107,150 · week ending 2024-03-08 Shares traded in the week: 32,530 · week ending 2024-03-15 Shares traded in the week: 20,585 · week ending 2024-03-22 Shares traded in the week: 20,485 · week ending 2024-03-28 Shares traded in the week: 43,365 · week ending 2024-04-05 Shares traded in the week: 47,585 · week ending 2024-04-12 Shares traded in the week: 43,075 · week ending 2024-04-19 Shares traded in the week: 139,310 · week ending 2024-04-26 Shares traded in the week: 78,170 · week ending 2024-05-03 Shares traded in the week: 84,455 · week ending 2024-05-10 Shares traded in the week: 38,595 · week ending 2024-05-17 Shares traded in the week: 62,510 · week ending 2024-05-24 Shares traded in the week: 36,550 · week ending 2024-05-31 Shares traded in the week: 85,465 · week ending 2024-06-07 Shares traded in the week: 56,410 · week ending 2024-06-14 Shares traded in the week: 40,730 · week ending 2024-06-21 Shares traded in the week: 193,100 · week ending 2024-06-28 Shares traded in the week: 39,710 · week ending 2024-07-05 Shares traded in the week: 368,105 · week ending 2024-07-12 Shares traded in the week: 114,700 · week ending 2024-07-19 Shares traded in the week: 53,825 · week ending 2024-07-26 Shares traded in the week: 34,945 · week ending 2024-08-02 Shares traded in the week: 53,110 · week ending 2024-08-09 Shares traded in the week: 40,935 · week ending 2024-08-16 Shares traded in the week: 33,035 · week ending 2024-08-23 Shares traded in the week: 30,560 · week ending 2024-08-30 Shares traded in the week: 17,440 · week ending 2024-09-06 Shares traded in the week: 37,280 · week ending 2024-09-13 Shares traded in the week: 58,320 · week ending 2024-09-20 Shares traded in the week: 19,430 · week ending 2024-09-27 Shares traded in the week: 23,985 · week ending 2024-10-04 Shares traded in the week: 21,055 · week ending 2024-10-11 Shares traded in the week: 18,930 · week ending 2024-10-18 Shares traded in the week: 13,630 · week ending 2024-10-25 Shares traded in the week: 21,480 · week ending 2024-11-01 Shares traded in the week: 14,805 · week ending 2024-11-08 Shares traded in the week: 56,255 · week ending 2024-11-15 Shares traded in the week: 31,395 · week ending 2024-11-22 Shares traded in the week: 18,045 · week ending 2024-11-29 Shares traded in the week: 29,090 · week ending 2024-12-06 Shares traded in the week: 64,725 · week ending 2024-12-13 Shares traded in the week: 37,995 · week ending 2024-12-20 Shares traded in the week: 27,720 · week ending 2024-12-27 Shares traded in the week: 20,465 · week ending 2025-01-03 Shares traded in the week: 13,105 · week ending 2025-01-10 Shares traded in the week: 14,150 · week ending 2025-01-17 Shares traded in the week: 19,215 · week ending 2025-01-24 Shares traded in the week: 20,875 · week ending 2025-01-31 Shares traded in the week: 16,865 · week ending 2025-02-07 Shares traded in the week: 14,265 · week ending 2025-02-14 Shares traded in the week: 15,395 · week ending 2025-02-21 Shares traded in the week: 19,020 · week ending 2025-02-28 Shares traded in the week: 25,165 · week ending 2025-03-07 Shares traded in the week: 18,030 · week ending 2025-03-14 Shares traded in the week: 11,610 · week ending 2025-03-21 Shares traded in the week: 15,785 · week ending 2025-03-28 Shares traded in the week: 30,500 · week ending 2025-04-04 Shares traded in the week: 27,175 · week ending 2025-04-11 Shares traded in the week: 9,580 · week ending 2025-04-17 Shares traded in the week: 13,370 · week ending 2025-04-25 Shares traded in the week: 10,285 · week ending 2025-05-02 Shares traded in the week: 612,310 · week ending 2025-05-09 Shares traded in the week: 61,235 · week ending 2025-05-16 Shares traded in the week: 26,910 · week ending 2025-05-23 Shares traded in the week: 22,990 · week ending 2025-05-30 Shares traded in the week: 24,020 · week ending 2025-06-06 Shares traded in the week: 25,010 · week ending 2025-06-13 Shares traded in the week: 20,085 · week ending 2025-06-20 Shares traded in the week: 31,365 · week ending 2025-06-27 Shares traded in the week: 12,120 · week ending 2025-07-03 Shares traded in the week: 18,710 · week ending 2025-07-11 Shares traded in the week: 15,605 · week ending 2025-07-18 Shares traded in the week: 18,975 · week ending 2025-07-25 Shares traded in the week: 21,995 · week ending 2025-08-01 Shares traded in the week: 21,710 · week ending 2025-08-08 Shares traded in the week: 12,985 · week ending 2025-08-15 Shares traded in the week: 22,495 · week ending 2025-08-22 Shares traded in the week: 17,755 · week ending 2025-08-29 Shares traded in the week: 22,205 · week ending 2025-09-05 Shares traded in the week: 22,540 · week ending 2025-09-12 Shares traded in the week: 17,350 · week ending 2025-09-19 Shares traded in the week: 27,540 · week ending 2025-09-26 Shares traded in the week: 26,150 · week ending 2025-10-03 Shares traded in the week: 60,005 · week ending 2025-10-10 Shares traded in the week: 65,470 · week ending 2025-10-17 Shares traded in the week: 45,870 · week ending 2025-10-24 Shares traded in the week: 35,915 · week ending 2025-10-31 Shares traded in the week: 26,130 · week ending 2025-11-07 Shares traded in the week: 34,420 · week ending 2025-11-14 Shares traded in the week: 43,610 · week ending 2025-11-21 Shares traded in the week: 20,410 · week ending 2025-11-28 Shares traded in the week: 28,045 · week ending 2025-12-05 Shares traded in the week: 1,625,195 · week ending 2025-12-12 Shares traded in the week: 99,925 · week ending 2025-12-19 Shares traded in the week: 122,025 · week ending 2025-12-26 Shares traded in the week: 46,485 · week ending 2026-01-02 Shares traded in the week: 45,290 · week ending 2026-01-09 Shares traded in the week: 44,485 · week ending 2026-01-16 Shares traded in the week: 39,485 · week ending 2026-01-23 Shares traded in the week: 59,220 · week ending 2026-01-30 Shares traded in the week: 38,285 · week ending 2026-02-06 Shares traded in the week: 31,325 · week ending 2026-02-13 Shares traded in the week: 18,995 · week ending 2026-02-20 Shares traded in the week: 59,370 · week ending 2026-02-27 Shares traded in the week: 40,220 · week ending 2026-03-06 Shares traded in the week: 2,347,940 · week ending 2026-03-13 Shares traded in the week: 813,635 · week ending 2026-03-20 Shares traded in the week: 208,915 · week ending 2026-03-27 Shares traded in the week: 104,600 · week ending 2026-04-02 Shares traded in the week: 169,905 · week ending 2026-04-10 Shares traded in the week: 38,582,520 · week ending 2026-04-17 Shares traded in the week: 1,314,895 · week ending 2026-04-24 Shares traded in the week: 339,855 · week ending 2026-05-01 Shares traded in the week: 256,790 · week ending 2026-05-08 Shares traded in the week: 276,325 · week ending 2026-05-15 Shares traded in the week: 172,695 · week ending 2026-05-22 Shares traded in the week: 291,455 · week ending 2026-05-29 Shares traded in the week: 292,010 · week ending 2026-06-05 Shares traded in the week: 114,545 · week ending 2026-06-12 Shares traded in the week: 52,625 · week ending 2026-06-18 Shares traded in the week: 110,230 · week ending 2026-06-26 Shares traded in the week: 133,470 · week ending 2026-07-02 Shares traded in the week: 78,280 · week ending 2026-07-10 Shares traded in the week: 79,540 · week ending 2026-07-17 Shares traded in the week: 68,925 · week ending 2026-07-24 Shares traded in the week: 35,960 · week ending 2026-07-31 Shares traded in the week: 40,305 · week ending 2026-08-07 Shares traded in the week: 28,810 · week ending 2026-08-14 Shares traded in the week: 21,245 · week ending 2026-08-21 Shares traded in the week: 30,425 · week ending 2026-08-28 Shares traded in the week: 28,970 · week ending 2026-09-04 Shares traded in the week: 186,515 · week ending 2026-09-11 Shares traded in the week: 97,485 · week ending 2026-09-18 Shares traded in the week: 107,090 · week ending 2026-09-25 Shares traded in the week: 104,200 · week ending 2026-10-02 Shares traded in the week: 84,700 · week ending 2026-10-09 Shares traded in the week: 115,100 · week ending 2026-10-16 2022 2023 2024 2025 2026 Prediction locked on 2026-08-19 · closing price $7.80
Yahoo Finance · daily closing prices · saved 2026-10-17 · expected result window 2026-10-19 to 2026-10-19 View live chart

Market snapshot

What the company is worth and what it owns and owes, on the date its data was checked

Spot Usd Per Ads
$3.20
Spot As Of
2026-10-16
Spot Kind
settled close
Spot Note
The 2026-10-16 (Friday) close of US$3.20 per ADS, read from data/prices/IMMP.json through lib/prices.mjs closeOnOrBefore. The cache was fetched on 2026-10-17, after that session closed, so this is a settled close and not an intraday snapshot. BPIQ fetch_company_info on 2026-10-17 agrees: last_price 3.20, prvious_close [sic] 3.21. Every per-share figure in this record is on the post-2026-09-28 basis of 1 ADS = 200 ordinary shares.
Listing
Dual-listed. Ordinary shares on the ASX under IMM. American Depositary Shares (ADS) on the Nasdaq Global Market under IMMP. Depositary: The Bank of New York Mellon under the deposit agreement dated 2012-04-16.
Ads Ratio
Current
1 ADS = 200 ordinary shares
Previous
1 ADS = 10 ordinary shares
Effective
2026-09-28
Factor
20
Ads On Issue Before
approximately 32.8 million
Ads On Issue After
approximately 1.64 million
Old Cusip
45257L108
New Cusip
45257L207
Reason
Cure the Nasdaq minimum bid price deficiency notified 2026-04-27 (compliance period to 2026-10-26). Ordinary shares on issue unchanged at 1,473,721,306; no shares issued or cancelled; fractional ADS entitlements paid in cash.
Outcome
Nasdaq confirmed by letter dated 2026-10-12 that the ADS closed at or above US$1.00 for 10 consecutive business days, 2026-09-28 to 2026-10-09, and closed the matter.
Sources
Immutep 6-K filed 2026-09-22, Exhibit 99.1 'Change to American Depositary Share Ratio', dated 2026-09-21 - https://www.sec.gov/Archives/edgar/data/1506184/000119312526397189/d79097dex991.htm, Immutep 6-K filed 2026-10-14, Exhibit 99.1 'Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement', dated 2026-10-13 - https://www.sec.gov/Archives/edgar/data/1506184/000119312526420840/d36112dex991.htm
Tag
VERIFIED - Immutep 6-K exhibits filed 2026-09-22 and 2026-10-14
Ordinary Shares
1,473,721,306
Ordinary Shares As Of
2026-06-30
Ordinary Shares Note
1,473,721,306 at 2026-06-30 per note 23 of the FY26 annual financial report (6-K filed 2026-09-02), and stated as unchanged in the ADS-ratio release of 2026-09-21. EDGAR XBRL dei:EntityCommonStockSharesOutstanding still shows 1,460,389,575 at 2025-06-30, because the FY26 Form 20-F had not been filed by 2026-10-17.
Ads Equivalents Basic
7,368,606.53
Economic Share Count Ads
7,452,053
Economic Share Count Note
(1,473,721,306 ordinary shares + 16,689,221 nil-exercise-price performance rights outstanding at 2026-06-30, of which 4,695,065 are held by non-executive directors and 11,994,156 by executives) / 200 = 7,452,053 ADS-equivalents. There were no unlisted options, warrants or convertible notes on issue at 2026-06-30. The performance rights are counted because a nil exercise price makes every one of them in the money; most are unvested and conditional on continued service, so including them lowers every per-share figure by about 1.1% and is the conservative choice.
Market Cap Usd
$23,579.54B
Market Cap Note
Recomputed: 1,473,721,306 / 200 = 7,368,606.53 ADS-equivalents x US$3.20. BPIQ reports 23,579,542 - the same figure to the dollar, so on this sweep BPIQ used the last price and the current share count. The ADS line actually on issue (about 1.64M ADS) is only about 22% of the company; the other 78% trades as ordinary shares on the ASX.
Cash Aud
$68,873.04B
Cash Composition
A$63.7M cash and cash equivalents plus A$5.2M term deposits (3-12 month maturities, classed as short-term investments)
Fx Aud Usd
0.696
Fx As Of
2026-10-16
Fx Source
ECB euro foreign exchange reference rates, cross rate via api.frankfurter.app, 2026-10-16
Cash Usd Equivalent
$47,927.37B
Debt Like Aud
7,508,609
Debt Like Note
No borrowings. Two debt-like items at 2026-06-30: A$6,461,083 of non-current accruals for contract manufacturing already performed, on deferred payment terms of up to 30 months with contractual interest (note 18), and A$1,047,526 of lease liabilities (A$290,149 current, A$757,377 non-current). Total A$7,508,609 = US$5,225,091 at 0.69588.
Debt Like Usd
5,225,091
Enterprise Value Usd Recomputed
-19,122,742
Enterprise Value Note
US$23,579,541 market capitalisation - US$47,927,374 cash + US$5,225,091 debt-like items = -US$19.1M. Negative: the market values the company at less than its June cash net of debt-like items, before any burn since June. BPIQ reports enterprise_value -5,264,826, which reconciles with neither its own cash field (68,873,044, which is A$ and not US$) nor the converted figure.
Quarterly Burn Aud Modelled
$12,000B
Quarterly Burn Note
A forward burn of A$12M per quarter (US$8.35M at 0.69588), modelled and tagged UNVERIFIED. No forward burn is disclosed. Guidance is a runway 'well into the first half of CY2028' from A$68.9M at 2026-06-30, which spread to 2028-03-31 implies about A$9.8M per quarter. A$12M is set above that average because the September 2026 quarter still carries TACTI-004 close-out costs, A$13.4M of trade payables at 2026-06-30 and a newly contracted 200 L manufacturing run. The Q1 FY27 quarterly activities report, due by 2026-10-31, will replace this figure.
Cash Per Ads Usd At June
$6.4M
Cash Floor Usd At Event
$4.4M
Cash Floor Note
lib/edge.mjs cashFloor at the program's readout.window.likeliest of 2026-10-19: (US$47,927,374 - US$5,225,091 - US$8,350,560 x 1.22 quarters + 0) / 7,452,053 = US$4.37 per ADS. Spot of US$3.20 sits 27% below it. Sensitivity: A$9M per quarter gives US$4.71, A$15M gives US$4.03.
Fifty Two Week High Usd
70.6
Fifty Two Week High Date
2025-12-08
Fifty Two Week Low Usd
3.06
Fifty Two Week Low Date
2026-10-15
Position In 52w Range Pct
0.2%
Position Note
Computed with lib/prices.mjs range52w and positionInRange as of 2026-10-16, on an ADJUSTED copy of the cache: every bar dated before 2026-09-28 multiplied by 20 (prices) and divided by 20 (volume), except the 2026-09-14 bar, which is already on the new basis. The adjustment exists because the committed cache splices two price scales (see data_quality_flags). On the raw cache the same calls return a low of 0.26, a high of 7.00 (the lone 2026-09-14 bar's intraday high) and a position of 43.6%, all of which are wrong. The adjusted figures agree with BPIQ's own fifty_two_week_high 70.60 and fifty_two_week_low 3.06, which BPIQ has already restated for the ratio change.
Multiple Off 52w Low
$1.05
Average Daily Dollar Volume Usd
86,003
Average Daily Volume Ads
21,714
Volume Note
Mean over the 14 sessions on the new basis with a close, 2026-09-29 to 2026-10-16, from the cache. Volume before 2026-09-28 is not comparable without dividing by 20.
Runway Company Stated
Well into the first half of CY2028 (FY26 annual report, 2026-08-31; Q4 FY26 quarterly report, 2026-07-30).
Runway Recomputed
Not independently recomputable from a disclosed burn. A$68.9M at the modelled A$12M per quarter lasts about 5.7 quarters from 2026-06-30, to about 2027-10; at the guidance-implied A$9.8M it lasts to about 2028-03. The guidance is consistent with a burn near A$10M per quarter, not with the A$38.9M outflow of Q4 FY26.
Debt
No borrowings at 2026-06-30. The convertible notes held by Ridgeback converted in full on 2025-07-18 (7,441,304 shares).

Ownership and flow

Who holds it, and who has been buying

Insider Pct
0%
Institutional Pct
1.1%
Retail Other Pct
98.9%
Ownership Note
BPIQ insider_own 0.00012 and tute_own 0.01129, the same values as on 2026-08-19 and carrying no timestamp. Both describe US filers only; most of the register is ASX-listed ordinary shares held by Australian holders who file neither with the SEC nor on a 13F. The residual is not a measured retail figure.
Hedge Fund Holders
0
Hedge Fund Note
fetch_company_hedge_fund_holdings returned an empty object; fetch_company_info reports hf_holding_count 0 and in_no_hfs true.
Short Interest Ads
46,784
Short Interest Settlement Date
2026-09-30
Short Interest Pct Of Ads On Issue
2.9%
Short Interest Pct Of Ads Equivalents
0.6%
Short Interest Note
FINRA consolidatedShortInterest, settlement 2026-09-30: 46,784 ADS short (new basis), average daily volume 23,076 ADS, days to cover 2.03. FINRA's own changePercent of -95.18% against the 2026-09-15 settlement (971,238 ADS) compares across the ratio change; on one basis 971,238 / 20 = 48,562, so the real change is about -3.7%. Against the roughly 1.64M ADS actually on issue the short is 2.85%; against all 7,368,607 ADS-equivalents it is 0.63%. BPIQ short_float 0.00681 sits near the second reading, so BPIQ divides by the whole company, not by the ADS line.
Insider Flow
BPIQ fetch_company_insider_transactions completed with no output on three attempts. The EDGAR submissions feed shows six Form 3 initial statements filed 2026-04-01 to 2026-04-16, every one with event date 2026-03-18, and no Form 4 at any time. So no insider transaction has been reported to the SEC since those Form 3s; the connector and the filing feed agree. Directors' dealings on the ASX register (Appendix 3Y notices) were not read this sweep.

Options chain

Whether the chain can price an event at all

Readable
No
Spot
$3.20
Nearest Strike Note
BPIQ fetch_company_options_data completed with no output on three attempts on 2026-10-17. On 2026-08-19 the same call returned four expiries and 28 contracts. A ratio change normally converts existing contracts into adjusted, non-standard contracts delivering a fraction of the old ADS count, so an empty standard chain is plausible, but it was not confirmed: the optional Yahoo cross-check returned 'Too Many Requests'.
Liquidity Confidence
None. No chain was returned, and none would price a US$24M company whose Nasdaq line trades about US$86,000 a day.

Past catalyst reactions

Cross-checked against the press feed

Method
Each row: BPIQ's intraday figure where it carries one, plus the event-window move from the committed price cache through lib/prices.mjs - the average of the two closes before the announcement day against the average of the announcement-day close and the next trading day's close (05-prediction-protocol.md). Every window lies wholly before the 2026-09-28 ratio change, so both ends are on the same 1 ADS = 10 ordinary basis and need no adjustment; the 2026-09-14 bar is excluded from the one window it touches. US reaction day = the Sydney release date, because Immutep releases before the ASX opens, which is the previous US evening.
Rows
Row 1
Date
2026-09-21
Event
ADS ratio change announced (1:10 to 1:200, effective 2026-09-28)
Window Move Pct
-6.6%
Press Check
One release plus 6-K; no other news that day.
Read
A technical change the market sold. The slide continued after the change took effect: 4.71 on 2026-09-29 to 3.20 on 2026-10-16 (-32% over 13 sessions on the new basis).
Row 2
Date
2026-09-11
Event
Focused efti strategy: registration-directed work only in PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma; next trials targeted 2H CY2027; root cause analysis finds an N-glycan difference between 200 L and 2,000 L manufactured efti
Window Move Pct
1.5%
Press Check
One release plus 6-K (2026-09-11). Volume 3.21M ADS, about 15 times the August average.
Read
Close-to-close +12.1% on the day, then -30% over the next ten sessions to 0.26 on 2026-09-25. The day rewarded a path; the fortnight priced the two-year wait and the unfunded trials.
Row 3
Date
2026-07-24
Event
ESMO 2026 abstract accepted: EFTISARC-NEO HRQoL ePoster
Window Move Pct
-2.6%
Press Check
Clean.
Read
The acceptance of the very abstract that is this catalyst moved the stock down. No information was priced as positive.
Row 4
Date
2026-07-13
Event
INSIGHT-003 mature OS 30.9 months, bundled with a TACTI-004 immune-monitoring update
Intraday Pct
6.9%
Window Move Pct
4.8%
Press Check
One combined release; a 6-K and a US patent grant followed 2026-07-14.
Read
Positive, modest, and on bundled news.
Row 5
Date
2026-06-04
Event
IMP761 positive interim Phase 1 at EULAR 2026
Intraday Pct
-4.6%
Window Move Pct
-7.2%
Press Check
Clean.
Read
Positive data, stock down. Sell-the-news.
Row 6
Date
2026-05-28
Event
Pooled five-trial ALC and survival analysis
Intraday Pct
-0.7%
Window Move Pct
0%
Press Check
Clean.
Read
No reaction to a secondary analysis of reported data.
Row 7
Date
2026-04-15
Event
FDA Orphan Drug Designation for efti in soft tissue sarcoma
Intraday Pct
-46.1%
Window Move Pct
80.7%
Press Check
Heavy coverage ('shares surge'). Volume 704M ADS that day.
Read
THE LARGEST POSITIVE MOVE IN THE TABLE, AND IT WAS ON SARCOMA. The cache resolves what BPIQ's two fields could not: close 0.31 on 2026-04-14, open about 1.00, close 0.54, then 0.58 the next day. BPIQ's +221% gap and -46% intraday are both right, for the open and for the fall from it. A meme-scale spike on a sub-dollar stock, which then faded to 0.43 by late May.
Row 8
Date
2026-03-13
Event
TACTI-004 Phase III discontinued for futility
Intraday Pct
-11.9%
Window Move Pct
-82.8%
Press Check
Five same-day items; no offering.
Read
The defining move. The cache confirms what BPIQ's -80% open gap implied: 2.76 to 0.48.
Row 9
Date
2025-12-22
Event
IMP761 positive Phase 1 update
Intraday Pct
0.7%
Window Move Pct
8.8%
Press Check
Clean.
Read
The intraday field understated a +8.8% two-day move.
Row 10
Date
2025-11-13
Event
CTOS 2025 oral: EFTISARC-NEO translational data
Window Move Pct
3.4%
Press Check
One release.
Read
Modest positive on a congress presentation of already-reported sarcoma data.
Row 11
Date
2025-10-20
Event
ESMO 2025: full EFTISARC-NEO primary-endpoint presentation
Window Move Pct
-1.7%
Press Check
One release; BPIQ's historical feed omits this row.
Read
THE CLOSEST PRECEDENT FOR THIS CATALYST: the same trial, the same congress, a presentation of data whose headline was already public. It moved the stock -1.7%.
Row 12
Date
2025-05-27
Event
EFTISARC-NEO met its primary endpoint
Window Move Pct
0.3%
Press Check
One release dated 2025-05-27; US markets were closed 2025-05-26.
Read
The trial's real result moved the stock +0.3%. BPIQ carries null for this row; the cache sizes it.
Row 13
Date
2024-11-14
Event
CTOS 2024: first EFTISARC-NEO data, median hyalinization about 50%
Intraday Pct
7.7%
Window Move Pct
7.5%
Press Check
One release.
Read
The first sarcoma data drew the largest of the sarcoma-congress reactions.
Median Note
Median window move across the eight clean, non-registrational data events (2024-11-14, 2025-05-27, 2025-10-20, 2025-11-13, 2025-12-22, 2026-05-28, 2026-06-04, 2026-07-13): +1.81%. Across the four EFTISARC-NEO data events alone: also +1.81%.
Missing Row Note
fetch_company_historical_catalysts (called as fetch_all_historical_catalysts with tickers [IMMP]) returned 21 rows. It still omits the 2025-10-20 ESMO 2025 presentation and has no row for the 2026-09-11 strategy release or the ratio change.

Company data-quality flags

  • THE PRICE CACHE SPLICES TWO SCALES. data/prices/IMMP.json holds bars up to 2026-09-25 on the old 1 ADS = 10 ordinary basis (about 0.26-0.40 in August-September 2026) and bars from 2026-09-29 on the new 1 ADS = 200 basis (3.20-4.87). 2026-09-28, the effective date, is a null bar although Nasdaq counted it as a trading day at or above US$1.00. 2026-09-14 is a lone new-basis bar (close 6.60, volume 25,415) between two old-basis bars (0.37 and 0.33); 6.60 / 20 = 0.33. The fetch of 2026-10-17 reported that the source now returns the old bars at 20 times their stored values, and the fetcher never overwrites a stored bar. Every lib/prices.mjs computation that spans 2026-09-28 reads mixed scales. This record adjusts explicitly wherever it uses one (C.4 range) and says so; the cache itself is outside this analysis's lane and was not repaired.
  • The 2026-08-19 bar is an intraday snapshot frozen into the cache: stored close 0.3964 on volume 44,352, against a source close of 0.39 (7.80 on the new basis).
  • FINRA's changePercent for the 2026-09-30 settlement (-95.18%) compares a new-basis short count with an old-basis one. The real change is about -3.7%.
  • BPIQ enterprise_value -5,264,826 reconciles with neither its cash field nor the recomputed figure. BPIQ cash 68,873,044 is in A$ while market_cap is in US$, as on 2026-08-19.
  • BPIQ fetch_company_options_data and fetch_company_insider_transactions both completed with no output on three attempts. The insider result agrees with EDGAR (no Form 4 filed). The options result could not be cross-checked (Yahoo throttled).
  • BPIQ marks row 18031 (efti + Keytruda, 1L HNSCC) Failed / Discontinued, while the company's 2026-09-11 release names PD-L1-negative head and neck cancer as a registration-directed focus with Fast Track designation. Left unresolved.
  • EDGAR XBRL dei:EntityCommonStockSharesOutstanding is a year old (2025-06-30, 1,460,389,575) because the FY26 Form 20-F had not been filed by 2026-10-17. The current count comes from the FY26 annual report and the 2026-09-21 release.
  • BPIQ's historical-catalyst feed omits the 2025-10-20 ESMO 2025 presentation, the 2026-09-11 strategy release and the 2026-09-21 ratio change, and its intraday field understates two-day moves (2025-12-22: +0.73% intraday against +8.76% over the window).
  • Correction to the 2026-08-19 record: its short interest of 0.82% 'of ADS outstanding' divided by all ordinary shares expressed as ADS (146,038,958), not by the ADS line actually on issue (about 32.8 million before the ratio change). On the ADS line the July short was about 3.6%.
  • Correction to the 2026-08-19 record: the orphan-designation move of 2026-04-15 recorded as unreadable is readable from the cache: +80.65% over the event window on 704M ADS of volume.
  • Drug names remain dirty: leading and trailing spaces on several rows, five spellings of one molecule. Names are trimmed here; nothing is keyed on them.

Company document

Background on the company in plain text. Each claim is tagged with the kind of evidence behind it.

IMMP — Immutep Limited

Company context · prepared 2026-10-17 · company sweep 2026-10-17 · USD · framework v6.2.0

How to read this. Written for a curious reader with little or no background in science, medicine, the drug industry or finance. General terms are explained once in the glossary. All money figures are in US dollars (USD). Every fact carries one of three tags. [VERIFIED — source] means a primary source confirmed it, and the source is named. [UNVERIFIED] means it could not be confirmed. [WEB ESTIMATE — source, date] means it is a third-party figure or a labelled model.

Program analyses for this company are the sub-folders listed in C.2.

Two unit conventions, stated once. Immutep is an Australian company listed twice. Its ordinary shares trade in Australian dollars on the Australian Securities Exchange (ASX) under IMM. An American Depositary Share (ADS), a US-listed certificate standing for a fixed number of ordinary shares, trades on Nasdaq under IMMP. Since 2026-09-28 one ADS stands for 200 ordinary shares; before that it stood for 10. Every US-dollar price here is per ADS on the new basis. Australian-dollar figures are converted at AUD/USD 0.69588, the European Central Bank (ECB) reference cross rate for 2026-10-16 [WEB ESTIMATE — ECB reference rates via api.frankfurter.app, 2026-10-16].

C.0 Company-tier coverage — CLEARED

The company tier was re-run in full. The 2026-08-19 sweep was 59 days old, and the press feed has since carried the FY26 annual results (2026-08-31) and an ADS ratio change, so it was not current under 02-connectors.md § Company-sweep currency.

ToolStateNote / verbatim error
BPIQ fetch_company_infoCALLEDPrice, market capitalisation, 52-week range, cash, ownership. The 52-week fields are already restated for the ratio change. Enterprise value is unreconcilable (C.8).
BPIQ fetch_company_drugsCALLEDNine rows, all in C.2.
BPIQ fetch_company_historical_catalystsCALLEDCalled as fetch_all_historical_catalysts with tickers [IMMP], the form the connector now offers. 21 rows back to 2018.
BPIQ fetch_company_options_dataCALLEDCompleted with no output on three attempts. On 2026-08-19 it returned 28 contracts. Recorded as an empty result; see C.6.
BPIQ fetch_company_insider_transactionsCALLEDCompleted with no output on three attempts. The EDGAR filing feed agrees: no Form 4 filed. See C.5.
BPIQ fetch_company_press_releasesCALLED229 items, latest 2026-10-15.
optional BPIQ fetch_company_hedge_fund_holdingsCALLEDEmpty object.
optional BPIQ fetch_company_earnings_transcriptCALLEDNo output. The FY26 annual report carried the management commentary.
EDGAR submissionsCALLEDCIK 0001506184. Four 6-K filings since the last sweep were read in full (2026-09-02, 2026-09-11, 2026-09-22, 2026-10-14). No FY26 Form 20-F yet.
EDGAR XBRL companyconcept (dei:EntityCommonStockSharesOutstanding)CALLEDLatest value 1,460,389,575 at 2025-06-30. A year old, because the FY26 20-F is not yet filed. The current count, 1,473,721,306, comes from the FY26 annual report.
FINRA consolidatedShortInterestCALLEDSettlements 2026-08-14, 2026-08-31, 2026-09-15 and 2026-09-30 returned; 2026-10-15 not yet published.
optional Yahoo options chainBLOCKEDVerbatim response body: Too Many Requests, on the crumb endpoint and on the chain endpoint, across two attempts several minutes apart. Cost: the empty BPIQ chain cannot be cross-checked.

What this coverage does not cover. The price cache for this ticker exists now, but it is defective: it splices two price scales across the ratio change (C.8). Every figure below that reads price history says how it handled that.

C.1 What the company is

Immutep is an Australian biotechnology company built around one protein, lymphocyte activation gene-3 (LAG-3). Its lead drug is eftilagimod alfa (efti), a soluble manufactured form of LAG-3 that switches the immune system on. Six of its nine pipeline rows are efti. The one separate asset is IMP761, an antibody that uses LAG-3 to damp the immune system down in autoimmune disease. It has no product revenue; its income is licence payments, research-material sales and research tax incentives [VERIFIED — FY26 annual report, 6-K filed 2026-09-02].

What changed since 2026-08-19.

  1. A narrower plan for efti. On 2026-09-11 the company said registration-directed work will focus on two settings only: head and neck cancer with no PD-L1 expression (CPS < 1), and soft tissue sarcoma before surgery. Next trials are targeted for 2H CY2027, “subject to final decisions on trial design, regulatory interactions, manufacturing timelines, partnering and resources” [VERIFIED — 6-K filed 2026-09-11].
  2. A manufacturing explanation for the Phase 3 failure. The same release says the root cause analysis found “structural differences” between the efti used in TACTI-004 (made only at 2,000 L scale) and the efti used in earlier positive trials (200 L scale), “e.g. a subtle difference in N-glycan structure”. A new 200 L run is contracted. The analysis is not finished [VERIFIED — 6-K filed 2026-09-11].
  3. An ADS ratio change. From 2026-09-28 one ADS stands for 200 ordinary shares instead of 10, to cure a Nasdaq minimum-price deficiency. Nasdaq confirmed compliance on 2026-10-12 [VERIFIED — 6-K filed 2026-09-22; 6-K filed 2026-10-14].

The defining earlier fact still governs the valuation. On 2026-03-13 an independent data monitoring committee stopped TACTI-004, the company’s only Phase 3, for futility. The ADS fell from US$2.76 to US$0.48 on the old basis that day (US$55.20 to US$9.60 on the new basis) [VERIFIED — Immutep release 2026-03-13; data/prices/IMMP.json].

C.1a Delivery record and capabilities

ItemFindingSource / tag
Milestones metEFTISARC-NEO: topline 27 days after registry primary completion (2025-04-30 to 2025-05-27); presented at ESMO 2025 (2025-10-20) and CTOS 2025 (2025-11-13) as guided; ESMO 2026 abstract on the date guided in July. TACTI-004: interim futility analysis held in Q1 CY2026 as guided (outcome negative). IMP761: single ascending dose phase completed and presented at EULAR 2026 (June). Nasdaq: compliance regained on 2026-10-12, before the 2026-10-26 deadline.[VERIFIED — FY26 annual report; Immutep releases 2025-05-27, 2025-10-20, 2026-07-24; 6-K 2026-10-14]
Milestones missed or movedTACTI-004 Phase 3 stopped for futility (2026-03-13). AIPAC-003’s Phase 3 portion terminated (closed 2026-06-30). The head and neck late-stage path, discussed with the FDA in 2025, has not started and is now a 2H CY2027 target. The investigator-led breast cancer trial planned to start 2026-09-01 is on hold. No catalyst date on EFTISARC-NEO has slipped.[VERIFIED — Immutep releases 2026-03-13, 2026-09-11; CT.gov NCT05747794, NCT07102940]
Own manufacturing sitesNone. Immutep keeps global manufacturing rights for efti but owns no plant.[VERIFIED — FY26 annual report]
Contract manufacturersOne third-party vendor makes efti; the FY26 report does not name it. A$6,461,083 owed to it for manufacturing already performed is on deferred terms of up to 30 months, with interest. Ten GMP batches were made at 200 L; TACTI-004 used only 2,000 L product; a new 200 L run is contracted. The vendor’s name: no public record as of 2026-10-17.[VERIFIED — FY26 annual report note 18; 6-K 2026-09-11]
Launch experience and sales forceNone. No product has been sold and there is no sales force.[VERIFIED — FY26 annual report]
Partnerships and licencesDr. Reddy’s Laboratories SA, 2025-12-08: exclusive licence to efti outside North America, Europe, Japan and Greater China; US$20M upfront (US$10M repaid in June 2026 after TACTI-004), up to US$349.5M in milestones, double-digit royalties; Immutep supplies product. EOC Pharma: Greater China rights. Novartis (LAG525 antagonist antibody, licensed 2012): terminated by Novartis in August 2026. GSK (IMP731): technology transfer completed; data package under review. Merck & Co. supplies pembrolizumab to trials.[VERIFIED — FY26 annual report; Dr. Reddy's release 2025-12-08]

C.2 Pipeline — every program

Program (drug — indication)bpiq_drug_idStage & eventCatalyst (as disclosed)Date to a day?Analysed?Materiality to the stock
Eftilagimod alfa — metastatic breast cancer (AIPAC-003)13585Phase 2/3 UpdateTBANoNoUnfilled — not analysed. AIPAC-003 closed 2026-06-30; CT.gov lists it as terminated.
Eftilagimod alfa + pembrolizumab — soft tissue sarcoma (EFTISARC-NEO)17452Phase 2 Data readoutOctober 19, 2026YesYesMeaningful at the programme level, immaterial at the event level. Since 2026-09-11 it is one of the two indications the company intends to take into registration-directed trials, and it holds efti’s only Orphan Drug Designation. But this catalyst is a quality-of-life ePoster on a trial whose primary endpoint read out in May 2025.
Neoadjuvant eftilagimod alfa ± standard of care — early-stage HR+/HER2-negative breast cancer19277Phase 2 UpdateTBANoNoUnfilled — not analysed. On hold pending the root cause analysis.
IMP761 (LAG-3 agonist antibody) — autoimmune disease18203Phase 1 Data readoutH2 2026NoNoUnfilled — not analysed. The 2026-08-19 version judged this row dominant. 03a-company-spec.md C.2 allows no judgement on an unanalysed row, so that judgement is withdrawn.
Eftilagimod alfa + KEYTRUDA + chemotherapy — 1L non-small cell lung cancer (INSIGHT-003)16013Phase 1 UpdateTBANoNoUnfilled — not analysed. Mature median overall survival 30.9 months, single-arm (2026-07-13).
Eftilagimod alfa + avelumab — solid tumours, urothelial cancer18032Failed DiscontinuedTBANoNoUnfilled — not analysed. Failed; kept as track record.
Eftilagimod alfa + KEYTRUDA — 1L non-small cell lung cancer (TACTI-004)13791Failed DiscontinuedTBANoNoUnfilled — not analysed. Failed: stopped for futility 2026-03-13. BPIQ now sets has_catalyst false here; it was true on 2026-08-19.
IMP761 — COVID-1914910Failed DiscontinuedTBANoNoUnfilled — not analysed. Failed.
Eftilagimod alfa + KEYTRUDA — 1L head and neck squamous cell carcinoma (TACTI-003)18031Failed DiscontinuedTBANoNoUnfilled — not analysed. BPIQ marks it failed, but the company named PD-L1-negative head and neck cancer as a registration-directed focus on 2026-09-11. See C.8.

Two of nine rows carry a pending catalyst flag, and both are real: this program and IMP761.

C.3 Financial position

ItemValueAs ofTag
Cash and equivalentsA$68.87M (A$63.7M cash and equivalents plus A$5.2M term deposits) ≈ US$47.93M at 0.695882026-06-30[VERIFIED — FY26 annual report]; FX [WEB ESTIMATE — ECB reference rate, 2026-10-16]
Burn (per month)Not disclosed as a forward rate. Q4 FY26 operating outflow was A$38.9M, including TACTI-004 spending and the US$10M Dr. Reddy’s repayment. This analysis models A$4M per month (A$12M per quarter, US$8.35M) for the September quarter, above the guidance-implied average because TACTI-004 close-out, A$13.4M of trade payables and a new manufacturing run fall in it.Quarter to 2026-09-30, modelled[UNVERIFIED — modelled from guidance]
Runway as the company states it”Well into the first half of CY2028”2026-08-31[VERIFIED — FY26 annual report]
Runway recomputed (cash ÷ burn)At A$12M per quarter, about 5.7 quarters from 2026-06-30, to about 2027-10. The guidance implies about A$9.8M per quarter on average.2026-10-17[UNVERIFIED — derived]
DebtNo borrowings. Debt-like items: A$6.46M of interest-bearing deferred manufacturing payables (up to 30 months) and A$1.05M of leases; A$7.51M in all (≈ US$5.23M). The Ridgeback convertible notes converted in full on 2025-07-18.2026-06-30[VERIFIED — FY26 annual report notes 18, 19, 22]

Dilution history. No equity raise in the last 24 months, and none announced or withdrawn. The share count rose by 13.3M ordinary shares in FY26 (convertible-note conversion, warrant exercise, vested performance rights) [VERIFIED — FY26 annual report note 23]. Funding came from the Dr. Reddy’s licence instead.

DateInstrumentGross proceedsPriceSource
2025-12-08 (received 2026-01)Dr. Reddy’s licence upfront. Not equityUS$20Mn/a[VERIFIED — FY26 annual report]
2026-06Repayment of part of that upfront after TACTI-004−US$10Mn/a[VERIFIED — FY26 annual report]
2025-07-18Conversion of the last Ridgeback convertible notes: 7,441,304 shares at A$0.15nil cashA$0.15[VERIFIED — FY26 annual report note 19]

Is a raise before the next catalyst likely? Not before 2026-10-19. Before the 2H CY2027 trial start, likely, unless a partner funds the trial. A raise with the ADS 27% below the cash floor would be very dilutive [UNVERIFIED — judgement].

C.4 Valuation frame

ItemValueSource / tag
Share price (spot)US$3.20 per ADS, the settled close of 2026-10-16 (≈ A$0.023 per ordinary share)[VERIFIED — data/prices/IMMP.json via lib/prices.mjs closeOnOrBefore; BPIQ last_price 3.20, 2026-10-17]
Market capitalisationUS$23.58M: 1,473,721,306 ordinary shares ÷ 200 = 7,368,607 ADS-equivalents × US$3.20. BPIQ reports US$23,579,542, the same figure[VERIFIED — FY26 annual report note 23 × spot]
Enterprise value−US$19.1M: US$23.58M − US$47.93M cash + US$5.23M debt-like items. BPIQ reports −US$5,264,826, unreconcilable (C.8)[UNVERIFIED — recomputed; depends on the FX rate and on the debt-like classification]
52-week high / lowUS$70.60 (2025-12-08) / US$3.06 (2026-10-15), on the new basis[VERIFIED — lib/prices.mjs range52w on an adjusted series; BPIQ 70.60 / 3.06 agree]
Position in the 52-week range, computed off the last price0.2%[VERIFIED — lib/prices.mjs positionInRange on the adjusted series]
Multiple off the 52-week low1.05×[VERIFIED — 3.20 ÷ 3.06]
Economic share count7,452,053 ADS-equivalents: (1,473,721,306 ordinary shares + 16,689,221 nil-price performance rights) ÷ 200. No options, warrants or convertibles on issue[VERIFIED — FY26 annual report notes 23 and 34, at 2026-06-30]

How the range was produced. The committed cache splices two price scales (C.8). Run as 03a-company-spec.md C.4 instructs, range52w and positionInRange on the raw cache return a low of 0.26, a high of 7.00 and a position of 43.6%, all wrong. The figures above come from the same two calls on an adjusted copy: every bar before 2026-09-28 multiplied by 20, except the 2026-09-14 bar, which is already on the new basis. The adjusted figures match BPIQ’s restated 52-week fields.

What the numbers say in plain terms. The market values the whole company at about US$19M less than its June cash net of debt-like items. Net of the modelled burn to 2026-10-19, the cash floor is US$4.37 per ADS, and spot sits 27% below it (lib/edge.mjs cashFloor; inputs above). The ADS has fallen 60% since 2026-08-19: US$0.40 then on the old basis is US$8.00 on the new basis. The fall came in two steps. After the 2026-09-11 strategy release the ADS fell 30% in ten sessions. After the ratio change took effect it fell another 32% in thirteen sessions.

The listing deadline, resolved. Nasdaq notified Immutep on 2026-04-27 that its ADS had closed below US$1.00 for 30 business days. The ratio change of 2026-09-28 lifted the price above US$1.00, and Nasdaq confirmed compliance on 2026-10-12 after ten qualifying sessions, 2026-09-28 to 2026-10-09 [VERIFIED — 6-K filed 2026-10-14]. The company notes that a new deficiency within 12 months of a ratio change gets no fresh compliance period, which is why it chose a large ratio [VERIFIED — 6-K filed 2026-09-22]. At US$3.20 the margin above US$1.00 is still large.

C.5 Ownership and flow

Holder typeShareNoteSource
Insider0.012%Unchanged from 2026-08-19; describes US filers only[VERIFIED — BPIQ fetch_company_info, 2026-10-17; no timestamp]
Institutional1.13%Same caveat[VERIFIED — BPIQ fetch_company_info, 2026-10-17; no timestamp]
Retail / other~98.9% residualNot a measured figure[UNVERIFIED — residual]
Short interest46,784 ADS = 2.85% of the ~1.64M ADS on issue (0.63% of all ADS-equivalents); days to cover 2.03Settlement 2026-09-30, new basis[VERIFIED — FINRA consolidatedShortInterest; ADS count from 6-K filed 2026-09-22]

Read the split with the dual listing in mind. Only about 1.64M ADS exist after the ratio change, about 22% of the company. The rest trades as ordinary shares on the ASX, mostly held by Australian holders who file with neither the SEC nor on a 13F. A 1.13% institutional reading describes the American slice.

Short interest is small and the ratio change distorts FINRA’s own arithmetic. FINRA’s change of −95.18% between 2026-09-15 (971,238 ADS) and 2026-09-30 (46,784 ADS) compares two bases. On one basis 971,238 ÷ 20 = 48,562, so the real change is about −3.7%. Correction to the 2026-08-19 version: it divided its short count by all ordinary shares expressed as ADS (146M) and called the result 0.82% “of ADS outstanding”. The ADS line then on issue was about 32.8M, so that short was about 3.6% of the ADS line. There is no squeeze set-up either way.

Liquidity is very thin. Over the 14 sessions on the new basis, the ADS traded about 21,700 ADS a day, about US$86,000 [VERIFIED — data/prices/IMMP.json].

Insider flow: nothing reported. BPIQ returned nothing three times. EDGAR shows six Form 3 initial statements filed 2026-04-01 to 2026-04-16, every one with event date 2026-03-18, and no Form 4 at any time [VERIFIED — EDGAR submissions, 2026-10-17]. So no director or officer has reported a trade to the SEC since. ASX director-interest notices (Appendix 3Y) were not read. No open-market buying at a price 27% below cash is visible.

Nobody is positioned through a fund. hf_holding_count is 0 and the holdings call returns an empty object [VERIFIED — BPIQ, 2026-10-17].

C.6 Options chain and its readability

Plain takeaway: there is no options chain to read. BPIQ returned no chain on three attempts. After a ratio change, existing contracts are normally converted into adjusted contracts on the old deliverable, so a standard chain may genuinely not exist yet. The optional Yahoo cross-check was throttled, so this could not be confirmed. Either way, no options market would price an event on an ADS line trading US$86,000 a day.

ItemValueNote
SpotUS$3.20Settled close 2026-10-16
Nearest listed strike to spotnone returnedBPIQ no output ×3
Expiry nearest the next catalystnone returned
At-the-money straddle ÷ spotnot computable
Front implied volatilityunreadable
Open interest at that strikenone returned
Liquidity confidenceNone

C.7 Reaction to past catalysts

The move columns: BPIQ’s intraday figure where it has one, and the event-window move from the price cache through lib/prices.mjs: the average of the two closes before the announcement day against the average of the announcement-day close and the next close. Every window lies wholly before the 2026-09-28 ratio change, so both ends share one basis; the 2026-09-14 bar is excluded from the one window it touches. This is new: the 2026-08-19 sweep had no cache and could not size four of these rows.

DateEventIntraday moveSame-day press-feed checkRead
2026-09-21ADS ratio change announcedn/a; window −6.56%One release and a 6-KA technical change, sold. The slide continued after it took effect: −32% over 13 sessions.
2026-09-11Focused efti strategy; next trials 2H CY2027; manufacturing findingn/a; window +1.45%, day +12.1% on 3.2M ADSOne release and a 6-KThe day rewarded a path; the next ten sessions fell 30% as the wait and the unfunded trials were priced.
2026-07-24ESMO 2026 abstract accepted (this catalyst)n/a; window −2.56%CleanThe acceptance of this very abstract moved the stock down.
2026-07-13INSIGHT-003 mature survival, bundled with a TACTI-004 update+6.88%; window +4.76%One combined releasePositive, modest, bundled.
2026-06-04IMP761 interim Phase 1 at EULAR−4.64%; window −7.23%CleanPositive data, stock down: sell-the-news.
2026-05-28Pooled five-trial lymphocyte and survival analysis−0.65%; window 0.00%CleanNo reaction to a secondary analysis.
2026-04-15FDA Orphan Drug Designation, soft tissue sarcoma−46.14% (from the open); window +80.65%Heavy coverage; 704M ADS tradedThe largest positive move, and it was on sarcoma. Correction to the 2026-08-19 version, which recorded it as unreadable: the cache shows a close of 0.31 before, an open near 1.00 and closes of 0.54 and 0.58. BPIQ’s +221% gap and −46% intraday were both right. It faded to 0.43 by late May.
2026-03-13TACTI-004 stopped for futility−11.89%; window −82.79%Five same-day items; no offeringThe defining move.
2025-12-22IMP761 positive Phase 1 update+0.73%; window +8.76%CleanThe intraday figure understated the move.
2025-11-13CTOS 2025: EFTISARC-NEO translational datan/a; window +3.36%One releaseModest positive.
2025-10-20ESMO 2025: full EFTISARC-NEO primary datan/a (BPIQ omits the row); window −1.68%One releaseThe closest precedent for 2026-10-19: the same trial and congress, headline already public.
2025-05-27EFTISARC-NEO met its primary endpointnull in BPIQ; window +0.26%One release; US closed 2025-05-26The trial’s real result barely moved the stock.
2024-11-14CTOS 2024: first EFTISARC-NEO data+7.69%; window +7.53%One releaseThe first sarcoma data drew the largest sarcoma-congress reaction.

What the rows say together. The median window move across the eight clean, non-registrational data events (2024-11-14, 2025-05-27, 2025-10-20, 2025-11-13, 2025-12-22, 2026-05-28, 2026-06-04, 2026-07-13) is +1.81%. The four EFTISARC-NEO data events alone have the same median. This stock does not pay for incremental good data. It paid enormously for one regulatory fact (the orphan designation) and punished one failure catastrophically.

Rows missing from BPIQ. fetch_company_historical_catalysts omits the 2025-10-20 ESMO 2025 presentation, the 2026-09-11 strategy release and the 2026-09-21 ratio change.

C.8 Company data-quality flags

  • The price cache splices two scales (named data defect). data/prices/IMMP.json holds bars to 2026-09-25 on the old basis (1 ADS = 10 ordinary) and bars from 2026-09-29 on the new basis (1 ADS = 200). 2026-09-28, the effective date, is a null bar, although Nasdaq counted it as a qualifying session. 2026-09-14 is a lone new-basis bar (close 6.60, volume 25,415) between two old-basis bars (0.37 and 0.33); 6.60 ÷ 20 = 0.33. The fetch of 2026-10-17 reported that the source now returns old bars at 20 times their stored values, and the fetcher never overwrites. Any lib/prices.mjs computation that spans 2026-09-28 reads mixed scales. This document adjusts explicitly where it uses one (C.4) and keeps every C.7 window on one side. The cache was not repaired: it is outside this analysis’s lane.
  • An intraday bar is frozen in the cache: 2026-08-19 stored at 0.3964 on volume 44,352, against a source close of 0.39.
  • The corporate action is confirmed from primary sources: ratio 1:10 to 1:200, effective 2026-09-28, CUSIP 45257L108 to 45257L207, depositary BNY, ordinary shares unchanged at 1,473,721,306 (6-K filed 2026-09-22; completion confirmed in the 6-K filed 2026-10-14).
  • FINRA’s change figure spans the ratio change (−95.18% reported against about −3.7% real).
  • BPIQ enterprise_value (−5,264,826) is unreconcilable. Its cash (68,873,044) is in A$ while market_cap is in US$, as on 2026-08-19.
  • BPIQ options and insider calls returned no output three times each. The insider result agrees with EDGAR. The options result could not be cross-checked.
  • BPIQ and the company disagree on head and neck cancer. Row 18031 is marked failed; the 2026-09-11 release makes PD-L1-negative head and neck cancer a registration-directed focus with Fast Track designation. Left unresolved.
  • EDGAR XBRL’s share count is a year old (2025-06-30); the FY26 20-F is not yet filed.
  • BPIQ’s historical-catalyst feed is incomplete (C.7), and its intraday field can understate a two-day move (2025-12-22).
  • BPIQ has_catalyst on row 13791 is now false. The stale flag recorded on 2026-08-19 is fixed.
  • Correction: the 2026-08-19 short-interest percentage used the wrong denominator (C.5).
  • Correction: the 2026-08-19 orphan-designation move is readable (C.7).
  • Drug names remain dirty (leading and trailing spaces; several spellings of one molecule). Nothing is keyed on them.
  • BPIQ insider_own and tute_own carry no timestamp.

Sources

    BPIQ fetch_company_drugs IMMP, 2026-10-17 - nine rows BPIQ fetch_company_info IMMP, 2026-10-17 BPIQ fetch_all_historical_catalysts tickers [IMMP], 2026-10-17 - 21 rows BPIQ fetch_company_options_data IMMP, 2026-10-17 - no output on three attempts BPIQ fetch_company_insider_transactions IMMP, 2026-10-17 - no output on three attempts BPIQ fetch_company_press_releases IMMP, 2026-10-17 - 229 items to 2026-10-15 BPIQ fetch_company_hedge_fund_holdings IMMP, 2026-10-17 - empty object BPIQ fetch_company_earnings_transcript IMMP, 2026-10-17 - no output EDGAR submissions CIK 0001506184, 2026-10-17 EDGAR XBRL companyconcept dei:EntityCommonStockSharesOutstanding CIK 0001506184, 2026-10-17 Immutep 6-K filed 2026-09-02, Exhibit 99.1, FY26 Annual Report incl. financial statements - https://www.sec.gov/Archives/edgar/data/1506184/000119312526379062/d435000dex991.htm Immutep 6-K filed 2026-09-11, Exhibit 99.1, 'Immutep Outlines Focused Development Strategy for Eftilagimod Alfa' - https://www.sec.gov/Archives/edgar/data/1506184/000119312526389402/d127093dex991.htm Immutep 6-K filed 2026-09-22, Exhibit 99.1, 'Change to American Depositary Share Ratio' - https://www.sec.gov/Archives/edgar/data/1506184/000119312526397189/d79097dex991.htm Immutep 6-K filed 2026-10-14, Exhibit 99.1, 'Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement' - https://www.sec.gov/Archives/edgar/data/1506184/000119312526420840/d36112dex991.htm FINRA consolidatedShortInterest symbolCode IMMP, settlements 2026-08-14, 2026-08-31, 2026-09-15 and 2026-09-30, read 2026-10-17 data/prices/IMMP.json via lib/prices.mjs, fetched 2026-10-17 ECB euro reference rates via api.frankfurter.app, AUD/USD 2026-06-30 0.68871 and 2026-10-16 0.69588 Yahoo Finance options IMMP, 2026-10-17 - BLOCKED, body 'Too Many Requests'